Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 in DIPG and H3K27-altered HGG
NCT06838676Phase 2Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of dimethylaminomicheliolide in diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG) (2 cohorts), sponsored by Nationwide Children's Hospital. Primary endpoints: Overall Survival at 60 months and Objective Response Rate. Started Jul 2025; status: recruiting.
02
Drugs
dimethylaminomicheliolide
03
Conditions
diffuse intrinsic pontine glioma (DIPG)high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT06838676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838676.